Raltegravir and Pregnancy

Researchers looked at the pharmacokinetics of raltegravir for use as an antiretroviral during pregnancy.  Despite decreased rates of absorption during pregnancy, the drug readily crossed the placenta.  Similar decreases in rates in non pregnant adults indicates that increased dosing during pregnancy is most likely unecessary.

 

Citation:
Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M; IMPAACT 1026s study team. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):375-81.

 

Abstract

Original Article (subscription may be required)